Farallon Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Farallon Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-150,697	Closed	-$2.01M	–	110
2019 Q4	$2.01M	Hold	150,697	–	–	0.01%	114
2019 Q3	$1.34M	Buy	150,697 +697	+0.5%	+$7.64K	0.01%	98
2019 Q2	$2.14M	Hold	150,000	–	–	0.01%	100
2019 Q1	$4.93M	Buy	150,000 +2,083	+1%	+$107K	0.04%	87
2018 Q4	$8.79M	Buy	147,917 +12,500	+9%	+$1.23M	0.06%	83
2018 Q3	$19M	Buy	135,417 +29,872	+28%	+$3.63M	0.11%	69
2018 Q2	$13M	Buy	+105,545	New	+$8.97M	0.08%	71
2016 Q3	–	Sell	-69,900	Closed	-$5.02M	–	70
2016 Q2	$5.02M	Hold	69,900	–	–	0.07%	56
2016 Q1	$5.6M	Buy	69,900 +15,000	+27%	+$1.18M	0.05%	68
2015 Q4	$4.14M	Buy	54,900 +35,625	+185%	+$5.72M	0.04%	62
2015 Q3	$7.39M	Buy	19,275 +108	+0.6%	+$48.7K	0.1%	66
2015 Q2	$7.96M	Buy	19,167 +8,334	+77%	+$3.49M	0.11%	70
2015 Q1	$5.15M	Buy	10,833 +5,833	+117%	+$2.77M	0.08%	79
2014 Q4	$1.85M	Hold	5,000	–	–	0.03%	82
2014 Q3	$1.18M	Buy	+5,000	New	+$1.13M	0.02%	81

Other funds holding LRMR

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Farallon Capital Management's LRMR Position: Q1 2020 in Review

Farallon Capital Management sold out of Larimar Therapeutics (LRMR) in Q1 2020, closing a stake of 150,697 shares — an estimated $2.01M sold.

Farallon Capital Management first reported a position in LRMR in Q3 2014 and held it in 15 quarters. The position peaked at $19M in Q3 2018. 42 funds tracked by Wall St. Rank hold LRMR as of Q1 2020.

Farallon Capital Management reported no remaining Larimar Therapeutics position as of Q1 2020 after selling out during the quarter.
Farallon Capital Management sold 150,697 Larimar Therapeutics shares in Q1 2020, an estimated $2.01M.
Farallon Capital Management first reported a position in Larimar Therapeutics in Q3 2014 and held it in 15 quarters.
Farallon Capital Management's Larimar Therapeutics position peaked at $19M in Q3 2018.
42 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2020.

Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.